Resumen acción GBT
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Global Blood Therapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.49 |
| 52 Week High | US$73.02 |
| 52 Week Low | US$21.65 |
| Beta | 0.46 |
| 1 Month Change | 1.02% |
| 3 Month Change | 98.98% |
| 1 Year Change | 169.54% |
| 3 Year Change | 45.26% |
| 5 Year Change | 106.30% |
| Change since IPO | 58.87% |
Noticias y actualizaciones recientes
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Recent updates
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Pfizer said to have had bidding war with Johnson & Johnson for Global Blood
Aug 24What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics
Aug 08Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil
Jul 14GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
Jun 29Global Blood Therapeutics: Powerhouse Of The Future
Jun 21Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07
Global Blood Therapeutics: Hitting A Growth Inflection
Apr 12Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Mar 12Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Global Blood Therapeutics: Revisiting A Stellar Grower
Dec 25IBI Research On Global Blood Therapeutics: Galvanized For Growth
Nov 30Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics: It Might Be Time To Buy The Dip
Oct 24Global Blood Therapeutics: Attempting To Classify The Investment
Aug 07Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why
Jun 12Global Blood Therapeutics announces employment inducement grants
Jun 04Global Blood Therapeutics: Increasing Specialization In SCD
May 09Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Feb 20
Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?
Jan 25Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?
Dec 29Health Check: How Prudently Does Global Blood Therapeutics (NASDAQ:GBT) Use Debt?
Dec 03Rentabilidad de los accionistas
| GBT | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.6% | -2.9% | -1.7% |
| 1Y | 169.5% | -0.2% | 22.9% |
Rentabilidad vs. Industria: GBT superó al sector US Biotechs , que obtuvo un rendimiento del -4.2% el año pasado.
Rentabilidad vs. Mercado: GBT superó al mercado US, que obtuvo un rendimiento del 14.1% el año pasado.
Volatilidad de los precios
| GBT volatility | |
|---|---|
| GBT Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: GBTha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: GBT(15%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2011 | 457 | Ted Love | www.gbt.com |
Resumen de fundamentos de Global Blood Therapeutics, Inc.
| Estadísticas fundamentales de GBT | |
|---|---|
| Capitalización bursátil | US$4.62b |
| Beneficios(TTM) | -US$322.46m |
| Ingresos (TTM) | US$234.86m |
19.7x
Ratio precio-ventas (PS)-14.3x
Ratio precio-beneficio (PE)¿Está GBT sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de GBT | |
|---|---|
| Ingresos | US$234.86m |
| Coste de los ingresos | US$4.45m |
| Beneficio bruto | US$230.41m |
| Otros gastos | US$552.87m |
| Beneficios | -US$322.46m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -4.78 |
| Margen bruto | 98.10% |
| Margen de beneficio neto | -137.30% |
| Ratio deuda/patrimonio | 491.7% |
¿Cómo se ha desempeñado GBT a largo plazo?
Ver rendimiento histórico y comparativa